DJPL On Expansion Mood

--By TC Correspondent

Deurali Janta Pharmaceuticals Pvt Ltd (DJPL) has launched new division called Nirog to manufacture pain-relief, anti-inflammatory, analgesic and musculoskeletal drugs whose demand has been soaring in the local market in recent years.

Executive Director Hari Bhakta   Sharma said, “This is basically a primary care division of DJPL to produce a ranges of medicines that boost immunity and that are necessary in trauma cases.” 

 Nirog is the fifth division of DJPL, a company with World Health Organization-Good Manufacturing Practice (WHO-GNP).

Its other four operating units are DJPL1, DJPL2, Suswasthya and Aarogyam that are currently producing 220 types of drugs holding five per cent share of the domestic market. 

Sharma said that the new division will help reduce the import of foreign medicines for primary care. With the introduction of new division, DJPL’s total investment has reached Rs 870 million. The company employs a total of 350 persons of which 85 are highly skilled, 55 skilled and 60 technical. 

The Nepali pharmaceutical companies totaling 45 in number meet less than 40 percent of the country’s demand for medicines. Sharma said that Nepal imports drugs manufactured by 258 foreign pharmaceuticals companies worth Rs 16.6 billion at present and DJPL wants the country to become self-reliant in the medicines. DJPL also provides its products for the research purpose to the foreign universities and media institutions. 

According to Sharma, DJPL now plants to set up a production plant for manufacturing herbal products and start extensive research on utilizing agro products in medicine industry. It also aims at exporting medicines to at least five international markets within 10 years, Sharma said, adding that the company is also planning to establish a separate division for veterinary medicine.